Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126040362 | 12604036 | 2 | F | 20160722 | 20160726 | 20160728 | 20160729 | EXP | RO-ABBVIE-16P-135-1686255-00 | ABBVIE | 71.35 | YR | M | Y | 83.00000 | KG | 20160729 | MD | RO | RO |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126040362 | 12604036 | 1 | PS | VIEKIRAX | OMBITASVIRPARITAPREVIRRITONAVIR | 1 | Oral | U | UNKNOWN | 206619 | FILM-COATED TABLET | BID | |||||||
| 126040362 | 12604036 | 2 | SS | VIEKIRAX | OMBITASVIRPARITAPREVIRRITONAVIR | 1 | U | UNKNOWN | 206619 | ||||||||||
| 126040362 | 12604036 | 3 | SS | EXVIERA | DASABUVIR | 1 | Oral | U | UNKNOWN | 206619 | FILM-COATED TABLET | BID | |||||||
| 126040362 | 12604036 | 4 | SS | EXVIERA | DASABUVIR | 1 | U | UNKNOWN | 206619 | ||||||||||
| 126040362 | 12604036 | 5 | SS | RIBAVIRIN. | RIBAVIRIN | 1 | Oral | U | UNKNOWN | 0 | FILM-COATED TABLET | ||||||||
| 126040362 | 12604036 | 6 | SS | RIBAVIRIN. | RIBAVIRIN | 1 | U | UNKNOWN | 0 | ||||||||||
| 126040362 | 12604036 | 7 | C | PROPRANOLOL | PROPRANOLOLPROPRANOLOL HYDROCHLORIDE | 1 | Oral | 0 | TABLET | ||||||||||
| 126040362 | 12604036 | 8 | C | PREDUCTAL | TRIMETAZIDINE DIHYDROCHLORIDE | 1 | Oral | 0 | TABLET | ||||||||||
| 126040362 | 12604036 | 9 | C | AFLEN | 2 | Oral | 0 | TABLET | |||||||||||
| 126040362 | 12604036 | 10 | C | BETASERC | BETAHISTINE | 1 | Oral | 0 | TABLET | ||||||||||
| 126040362 | 12604036 | 11 | C | GABARAN | 2 | Oral | 0 | TABLET |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126040362 | 12604036 | 1 | Hepatitis C |
| 126040362 | 12604036 | 2 | Hepatic cirrhosis |
| 126040362 | 12604036 | 3 | Hepatitis C |
| 126040362 | 12604036 | 4 | Hepatic cirrhosis |
| 126040362 | 12604036 | 5 | Hepatitis C |
| 126040362 | 12604036 | 6 | Hepatic cirrhosis |
| 126040362 | 12604036 | 7 | Varices oesophageal |
| 126040362 | 12604036 | 8 | Essential hypertension |
| 126040362 | 12604036 | 9 | Hemiparesis |
| 126040362 | 12604036 | 10 | Vertebrobasilar insufficiency |
| 126040362 | 12604036 | 11 | Hemiparesis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126040362 | 12604036 | LT |
| 126040362 | 12604036 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126040362 | 12604036 | Anaemia | |
| 126040362 | 12604036 | Ascites | |
| 126040362 | 12604036 | Diarrhoea | |
| 126040362 | 12604036 | General physical health deterioration | |
| 126040362 | 12604036 | Hepatic encephalopathy | |
| 126040362 | 12604036 | Leukocytosis | |
| 126040362 | 12604036 | Ocular icterus | |
| 126040362 | 12604036 | Renal failure | |
| 126040362 | 12604036 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126040362 | 12604036 | 1 | 20160711 | 20160725 | 0 | |
| 126040362 | 12604036 | 3 | 20160711 | 20160725 | 0 | |
| 126040362 | 12604036 | 5 | 20160711 | 20160725 | 0 |